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AbstractöThe e¡ect of the i.c.v. administration of antisense oligodeoxynucleotides directed against the K subunit of
di¡erent Gi-proteins (anti-GiK1, anti-GiK2, anti-GiK3) on the antinociception induced by the H1-antihistamines was
evaluated in the mouse hot-plate test. The administration of diphenhydramine (20 mg kg31 s.c.), pyrilamine (15 mg
kg31 s.c.) and promethazine (6 mg kg31 s.c.) produced an increase of the pain threshold which peaked 15 min after
injection. Pretreatment with anti-GiK1 (12.5 Wg per mouse i.c.v.), anti-GiK2 (25 Wg per mouse i.c.v.) and anti-GiK3 (25 Wg
per mouse i.c.v.), administered 24 and 18 h before test, prevented the antihistamine-induced antinociception. At the
highest e¡ective doses, none of the compounds used impaired motor coordination, as revealed by the rota rod test, nor
modi¢ed spontaneous motility and inspection activity, as revealed by the hole board test.
These results suggest an important role played by the Gi-protein pathway in the transduction mechanism involved in
the enhancement of the pain threshold produced by H1-antihistamines. ß 2002 IBRO. Published by Elsevier Science
Ltd. All rights reserved.
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The histamine H1-receptor antagonists are among the
most widely used medications in the world. These com-
pounds produce the inhibition of the e¡ects of histamine
mediated by H1 receptors such as smooth-muscle con-
traction in the respiratory and gastrointestinal tracts,
pruritus, sneezing by sensory-nerve stimulation, vasodi-
lation (Simons and Simons, 1994). Therefore, their most
common use is in the treatment of allergic disorders
(Rimer and Church, 1990). In addition to these well-
known peripheral e¡ects, H1-receptor antagonists pro-
duce various central inhibitory actions (Simons and
Simons, 1994). Antihistamines are widely used as adju-
vants in preoperative analgesia as well as in postopera-
tive pain. These compounds decrease the amount of
narcotic that is necessary, provides sedating, and other
antihistaminic e¡ects that are helpful in certain clinical
situations (Hupert et al., 1980; Sunshine et al., 1989).
H1-antagonists are also able to potentiate opioid analge-
sia in laboratory animals (Sun et al., 1985; Yeh, 1985;
Malec, 1987). It has also been observed that some anti-
histamines, such as hydroxyzine, diphenhydramine, pyril-
amine and promethazine, are endowed with analgesic
properties in both laboratory animals (Stambaugh and
Lane, 1983; Rumore and Schlichting, 1985; Sun et al.,
1985; Rumore and Schlichting, 1986) and humans
(Campos and Solis, 1980; Rumore and Schlichting,
1986).
Even if the analgesic properties of antihistamines are
well established, little is known about the intracellular
mechanism of action of these compounds. Recently, it
has been reported that the antinociception induced by
H1-receptor antagonists underlies the activation of a sig-
nal transduction mechanism operated by Gi-proteins.
The i.c.v. administration of pertussis toxin (PTX), com-
pound which selectively inactivates Gi-proteins, pre-
vented the increase of the pain threshold induced by
diphenhydramine, pyrilamine and promethazine in the
mouse hot-plate test (Galeotti et al., 1996, 1999). Gi-
proteins represent the most widespread modulatory sig-
nalling pathway in neurones (Holz et al., 1986) and their
involvement in the modulation of pain perception has
been determined. The administration of PTX produced
hyperalgesia and allodynia in laboratory animals
(Ohnishi et al., 1990; Galeotti et al., 1996; Womer et
al., 1997). A reduction of pain perception has also been
observed in knock-out mice lacking for the gene encod-
ing the subtype Go of the Gi-protein family (Jiang et al.,
1998). These data clearly indicate that a lack of function-
ality of Gi-proteins enhances the sensitivity to pain.
To elucidate the intracellular e¡ectors involved in the
mechanism of action of antihistamines, we decided to
further investigate the role of Gi-proteins in the diphen-
hydramine-, pyrilamine- and promethazine-induced
enhancement of the pain threshold by using an antisense
strategy. Antisense oligodeoxynucleotides (aODN) are
short synthetic DNA segments complementary to
sequences of an mRNA target. By forming DNA/
mRNA heteroduplexes, aODNs can transiently inacti-
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vate single genes. Since several G-protein subtypes
belong to the Gi family, in the present study we used
aODN against the K subunits of the Gi1, Gi2 and Gi3
proteins in order to determine the role of each subtype in




Male Swiss albino mice (23^30 g) from the Morini (San Polo
d’Enza, Italy) breeding farm were used. Fifteen mice were
housed per cage. The cages were placed in the experimental
room 24 h before the test for acclimatisation. The animals
were fed a standard laboratory diet and tap water ad libitum
and kept at 23 þ 1‡C with a 12-h light/dark cycle, light on at
07.00 h. All experiments were carried out in accordance with the
European Communities Council Directive of 24 November 1986
(86/609/EEC) for experimental animal care. All e¡orts were
made to minimise the number of animals used and their su¡er-
ing.
I.c.v. injection technique
I.c.v. administration was performed under ether anaesthesia,
according to the method described by Haley and McCormick
(1957). In brief, during anaesthesia, mice were grasped ¢rmly by
the loose skin behind the head. A 0.4-mm external diameter
hypodermic needle attached to a 10-Wl syringe was inserted per-
pendicularly through the skull and no more than 2 mm into the
brain of the mouse, where 5 Wl were then administered. The
injection site was 1 mm to the right or left from the midpoint
on a line drawn through to the anterior base of the ears. Injec-
tions were performed into the right or left ventricle, randomly.
To ascertain that the drugs were administered exactly into the
cerebral ventricle, some mice (20%) were injected with 5 Wl of
diluted 1:10 India ink and their brains examined macroscopi-
cally after sectioning. The accuracy of the injection technique
was evaluated and the percentage of correct injections was 95.
Hot-plate test
The method adopted was described by O’Callaghan and
Holtzman (1975). Mice were placed inside a stainless steel con-
tainer, which was set thermostatically at 52.5 þ 0.1‡C in a pre-
cision water-bath from KW Mechanical Workshop (Siena,
Italy). Reaction times (s), were measured with a stopwatch
before and 15, 30, 45 and 60 min after diphenhydramine, pyril-
amine and promethazine administration. The endpoint used was
the licking of the fore or hind paws. Those mice scoring less
than 12 and more than 18 s in the pretest were rejected (30%).
An arbitrary cut-o¡ time of 45 s was adopted.
The licking latency values reported in all ¢gures were eval-
uated in relation to the maximum analgesic e¡ect of diphen-
hydramine, pyrilamine and promethazine, which was reached
15 min after administration.
The doses of antihistamines used in the present research
resulted from data obtained by producing dose^response curves
in the hot-plate and rota rod tests which indicate them as the
highest e¡ective doses devoid of behavioural impairment
(Galeotti et al., 1999).
Hole board test
The hole board test was performed according to Galeotti et
al. (2001). The test consisted of a 40-cm square plane with 16
£ush mounted cylindrical holes (3 cm diameter) distributed four
by four in an equidistant, grid-like manner. Mice were placed on
the centre of the board one by one and allowed to move about
freely for a period of 10 min each. Two electric eyes, crossing
the plane from midpoint to midpoint of opposite sides, thus
dividing the plane into four equal quadrants, automatically sig-
nalled the movement of the animal (counts in 5 min) on the
surface of the plane (locomotor activity). Miniature photoelec-
tric cells, in each of the 16 holes, recorded (counts in 5 min) the
exploration of the holes (exploratory activity) by the mice. The
test was performed 24^18 h after the i.c.v. injection of degener-
ate ODN (dODN, 25 Wg per mouse) or aODN (12.5^25 Wg per
mouse). Twelve mice per group were tested.
Rota rod test
The apparatus consisted of a base platform and a rotating rod
with a diameter of 3 cm and a non-slippery surface. The rod was
placed at a height of 15 cm from the base. The rod, 30 cm in
length, was divided into ¢ve equal sections by six disks. Thus,
up to ¢ve mice were tested simultaneously on the apparatus,
with a rod-rotating speed of 16 r.p.m. The integrity of motor
coordination was assessed on the basis of the number of falls
from the rod in 30 s according to Vaught et al., (1985). Those
mice scoring less than three and more than six falls in the pretest
were rejected (20%). The performance time was measured before
(pretest) and 15, 30 and 45 min after s.c. administration of the
investigated compounds. Animals were i.c.v. pretreated 24 and
18 h prior to the test with dODN (25 Wg per mouse) or aODN
(12.5^25 Wg per mouse). Twelve mice per group were tested.
aODN
Phosphodiester oligonucleotides (ODNs) protected from ter-
minal phosphorothioate double substitution (capped ODNs)
against possible exonuclease-mediated degradation were pur-
chased by Tib Molbiol (Genova, Italy). The sequences of the
33-mer aODNs used in the present study were the following:
anti-Gi1K : 5P-G*C*T GTC CTT CCA CAG TCT CTT
TAT GAC GCC G*G*C-3P
anti-Gi2K : 5P-A*T*G GTC AGC CCA GAG CCT CCG
GAT GAC GCC C*G*A-3P
anti-Gi3K : 5P-G*C*C ATC TCG CCA TAA ACG TTT
AAT CAC GCC T*G*C-3P
All oligos were previously characterised by in vitro (immuno-
blotting) and in vivo (tail £ick) experiments (Ra¡a et al., 1994;
Sanchez-Blazquez et al., 1995; Sanchez-Blazquez and Garzon,
1998). A 33-mer fully dODN 5P-N*N*N NNN NNN NNN
NNN NNN NNN NNN NNN NNN N*N*N-3P (where N is
G, or C, or A, or T) was used as a control. ODNs were vehi-
culated intracellularly by an arti¢cial cationic lipid (DOTAP,
Sigma) to enhance both uptake and stability, as described pre-
viously (Capaccioli et al., 1993). aODN or dODN were prein-
cubated at 37‡C for 30 min with 13 WM DOTAP and supplied
to mice by i.c.v. injection of 5 Wl solution 18 and 24 h prior to
the behavioural tests.
Drugs
The following drugs were used: pyrilamine maleate, prome-
thazine hydrochloride (RBI); diphenhydramine hydrochloride,
D-amphetamine hydrochloride (De Angeli). Drugs were dis-
solved in isotonic (NaCl 0.9%) saline solution. Drug and
ODNs concentrations were prepared in such a way that the
necessary dose could be administered in a volume of 5 Wl by
i.c.v. injection or 10 ml kg31 by s.c. administration.
Statistical analysis
All experimental results are given as the mean þ S.E.M. Anal-
ysis of variance (ANOVA), followed by Fisher’s protected least
signi¢cant di¡erence (PLSD) procedure for post-hoc compari-
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son, was used to verify signi¢cance between two means. Data
were analysed with the StatView software for the Macintosh
(1992). P values of less than 0.05 were considered signi¢cant.
RESULTS
E¡ect of aODN against GiK subunits on
H1-antihistamines antinociception
Diphenhydramine (20 mg kg31 s.c.), pyrilamine (15
mg kg31 s.c.) and promethazine (6 mg kg31 s.c.) pro-
duced antinociception in the mouse hot-plate test (Fig. 1).
The antinociception induced by diphenhydramine (20
mg kg31 s.c.) was prevented by pretreatment with the
aODN against the K subunit of the Gi1 proteins (Fig. 1).
Anti-GiK1 (3.12^12.5 Wg per mouse i.c.v.) produced a
dose-dependent antagonism of the increase of the pain
threshold produced by diphenhydramine. The dose of
3.12 Wg per mouse i.c.v. was completely ine¡ective;
6.25 Wg per mouse i.c.v. partially prevented diphenhydr-
amine antinociception, even if the statistical signi¢cance
was not reached, while the doses of 12.5 Wg per mouse
i.c.v. reduced the licking latency up to a value compara-
ble to that produced by control animals (Fig. 1). Pre-
treatment with anti-GiK1 (12.5 Wg per mouse i.c.v.) also
prevented the antinociception induced by pyrilamine and
promethazine (Fig. 1).
The administration of an aODN against the K subunit
of the Gi2 proteins (6.25^25 Wg per mouse i.c.v.), dose-
Fig. 1. Prevention by aODN against the K subunit of Gi1 protein (3.12^12.5 Wg per mouse i.c.v.) of diphenhydramine (20 mg
kg31 s.c.), pyrilamine (15 mg kg31 s.c.) and promethazine (6 mg kg31 s.c.) antinociception in the mouse hot-plate test. Verti-
cal lines represent S.E.M. between 19 and 25 mice were tested. **P6 0.01 in comparison with dODN-treated mice.
Fig. 2. Prevention by aODN against the K subunit of Gi2 protein (6.25^25 Wg per mouse i.c.v.) of diphenhydramine (20 mg
kg31 s.c.), pyrilamine (15 mg kg31 s.c.) and promethazine (6 mg kg31 s.c.) antinociception in the mouse hot-plate test. Verti-
cal lines represent S.E.M. between 18 and 23 mice were tested. **P6 0.01 in comparison with dODN-treated mice.
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dependently prevented diphenhydramine-induced antino-
ciception (Fig. 2). At the concentration of 25 Wg per
mouse i.c.v., a complete prevention was obtained
whereas, at 6.25 Wg per mouse i.c.v., the aODN pretreat-
ment was ine¡ective. At the highest dose employed, anti-
GiK2 also antagonised the increase of the pain threshold
induced by both pyrilamine and promethazine (Fig. 2).
Similarly to anti-GiK2 pretreatment, the administra-
tion of an aODN against the K subunit of the Gi3 pro-
teins (6.25^25 Wg per mouse i.c.v.) antagonised, in a
dose-dependent manner, the antinociception produced
by diphenhydramine reaching its maximum antagonistic
e¡ect at the dose of 25 Wg per mouse i.c.v. (Fig. 3).
Pretreatment with anti-GiK3 also prevented antinocicep-
tion induced by pyrilamine and promethazine (Fig. 3).
A time-course of recovery from antihistamine antino-
ciception after aODN treatment was performed (data not
shown). The prevention of diphenhydramine, pyrilamine
and promethazine antinociception produced by anti-
Gi1K, anti-Gi2K and anti-Gi3K at the highest active
dose (12.5^25 Wg per mouse i.c.v.), disappeared 7 days
after the end of the aODN pretreatment (Fig. 4).
Anti-GiK1 (12.5 Wg per mouse i.c.v.), anti-GiK2 (25 Wg
per mouse i.c.v.) and anti-GiK3 (25 Wg per mouse i.c.v.)
Fig. 3. Prevention by aODN against the K subunit of Gi3 protein (6.25^25 Wg per mouse i.c.v.) of diphenhydramine (20 mg
kg31 s.c.), pyrilamine (15 mg kg31 s.c.) and promethazine (6 mg kg31 s.c.) antinociception in the mouse hot-plate test. Verti-
cal lines represent S.E.M.; between 20 and 27 mice were tested. **P6 0.01 in comparison with dODN-treated mice.
Fig. 4. Lack of e¡ect by pretreatment with an aODN to the K subunit of Gi1- (12.5 Wg per mouse i.c.v.), Gi2- (25 Wg per
mouse i.c.v.) and Gi3- (25 Wg per mouse i.c.v.) protein gene on diphenhydramine (20 mg kg31 s.c.), pyrilamine (15 mg kg31
s.c.) and promethazine (6 mg kg31 s.c.) antinociception 7 days after the i.c.v. injection of dODN (12.5^25 Wg per mouse
i.c.v.) or aODN. Vertical lines represent S.E.M. Fifteen mice per group were tested.
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did not produce any modi¢cation of the pain threshold
in comparison with dODN-treated mice when given
alone (Figs. 1^3).
Pretreatment with dODN never modi¢ed the animals’
sensitivity to the analgesic treatments in comparison with
saline- or DOTAP-injected mice (i.c.v.) and with unpre-
treated animals (data not shown).
E¡ect of H1-antihistamines on mouse behaviour
Pyrilamine, diphenhydramine and promethazine, at
the doses used in the present work, elicited their antino-
ciceptive e¡ect without changing gross behaviour of
mice.
The three H1-antihistamines investigated did not alter
the mice motor coordination as revealed by the rota rod
test (Fig. 5A). The rota rod endurance time of mice
treated with diphenhydramine (20 mg kg31 s.c.), pyril-
amine (15 mg kg31 s.c.) and promethazine (6 mg kg31
s.c.) was not modi¢ed in comparison with saline-treated
mice (Fig. 5A).
E¡ect of aODN on mouse behaviour
The motor coordination of mice pretreated with
aODN to Gi1K (12.5 Wg per mouse i.c.v.), Gi2K (25 Wg
per mouse i.c.v.) and Gi3K (25 Wg per mouse i.c.v.) was
evaluated by using the rota rod test. The motor coordi-
nation of aODN-treated groups was not impaired when
compared with that of dODN-treated mice (Fig. 5B).
The spontaneous motility and exploratory activity of
mice was not modi¢ed by administration of the above-
mentioned aODNs as revealed by the hole board test in
comparison with dODN-treated mice (Fig. 6). In the
same experimental conditions D-amphetamine (1 mg
kg31 i.p.), used as the reference drug, increased both
parameters evaluated (Fig. 6).
Furthermore, pyrilamine (15 mg kg31 s.c.), diphen-
hydramine (20 mg kg31 s.c.) and promethazine (6 mg
kg31 s.c.) did not modify the mice spontaneous motility
(data not shown).
DISCUSSION
The important role played by the Gi-protein family in
the mechanism of antinociceptive action of antihist-
amines is indicated by present results. In particular, the
involvement of Gi1, Gi2 and Gi3 protein subtypes has
been observed. The administration of aODN against
the K subunit of the above-mentioned Gi-proteins pro-
duced a dose-dependent prevention of the antinocicep-
tion induced by diphenhydramine, pyrilamine and
promethazine in the mouse hot-plate test.
These data also indicate that antihistamines exert
their antinociceptive e¡ect by acting centrally. The
antagonism of the diphenhydramine, pyrilamine and
promethazine antinociception, by i.c.v.-injected aODNs
shows that the site of action of antihistamines is centrally
located.
The inhibition of antihistamine-induced enhancement
of the pain threshold disappeared 7 days after pretreat-
ment with the aODNs. This return of sensitivity implies
both the total reversal of aODN-induced speci¢c inhibi-
tion of GiK expression and a lack of damage or toxicity
associated with aODN treatment. Pretreatment with the
anti-GiK ODNs at the highest e¡ective doses did not
modify the pain threshold, showing the absence of any
hyperalgesic e¡ect. Therefore, the prevention of antihist-
amine antinociception cannot be attributable to a direct
e¡ect on the pain threshold induced by the aODN. Fur-
thermore, the dODN did not modify diphenhydramine-,
Fig. 5. (A) E¡ect of diphenhydramine (20 mg kg31 s.c.), pyril-
amine (15 mg kg31 s.c.) and promethazine (6 mg kg31 s.c.) on
motor coordination in the mouse rota rod test. Antihistamines
were administered immediately before the test. (B) E¡ect of pre-
treatment with an aODN to the K subunit of Gi1- (12.5 Wg per
mouse i.c.v.), Gi2- (25 Wg per mouse i.c.v.) and Gi3- (25 Wg per
mouse i.c.v.) protein gene on motor coordination in the mouse
rota rod test. The test was performed 18 h after the last i.c.v.
injection of dODN (25 Wg per mouse i.c.v.) or aODN. Vertical
lines represent S.E.M. Twelve mice per group were tested.
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pyrilamine- and promethazine-induced antinociception in
comparison with naive or saline-i.c.v.-injected mice (data
not shown). This observation ruled out the possibility
that the antagonism exerted by aODNs may have
resulted from a sequence-independent action on cerebral
structures.
Diphenhydramine, pyrilamine and promethazine are
¢rst-generation H1-receptor antagonists (Simons and
Simons, 1994). H1 receptors are G-protein coupled
receptors that activate phospholipase C via a PTX-insen-
sitive mechanism (Arrang, 1994). By contrast, the antag-
onism exerted by anti-GiK indicates that the intracellular
mechanism of analgesic action of H1-antihistamines
involves the activation of PTX-sensitive G-proteins.
These results con¢rm and extend previous data which
evidenced that diphenhydramine, pyrilamine and pro-
methazine antinociception is prevented by the i.c.v.
administration of PTX (Galeotti et al., 1996; 1999). It
has been reported that ¢rst-generation H1-receptor
antagonists are receptor-independent G-protein activa-
tors in HL-60 cells, basophils and mast cells and that
such a mechanism of action might be responsible for
the stimulatory e¡ects of these compounds (Burde et
al., 1996). We can, therefore, suppose that a direct acti-
vation of the Gi-protein-mediated transduction system
might also be responsible for the increase of the pain
threshold induced by antihistamines. However, ¢rst-gen-
eration H1-receptor antagonists induce histamine release
from basophils and mast cells (Mota and Da Silva, 1960;
Mota, 1966; Lichtenstein and Gillespie, 1975) and
increase the histamine levels in the cerebrospinal £uid
(Suojaranta-Ylinen et al., 1991). Since it is well known
that histamine can modulate the release of several neuro-
transmitters (Hill, 1990), an involvement of neurotrans-
mitters di¡erent from histamine, activating Gi-proteins
as a signal transduction mechanism, downstream from
the initial receptor interaction, cannot be excluded.
Taking into account present observations together
with several literature data, it appears that the Gi-protein
system represents an essential intracellular step in the
induction of central antinociception. An increase of the
pain threshold, regardless the receptor subtype stimu-
lated or the neurotransmitter system involved, seems to
underlie the activation of Gi-proteins as a common intra-
cellular event. Hypofunctionality of PTX-sensitive
G-proteins not only induces hyperalgesia (Ohnishi et
al., 1990; Galeotti et al., 1996; Womer et al., 1997),
but also produces insensitivity to analgesic treatments.
Inactivation of Gi-proteins prevents the analgesic activity
of inhibitory neurotransmitters such as L-endorphins,
GABA, cathecholamines, purines (Chung et al., 1994;
Hoehn et al., 1988; Sawynok and Reid, 1988) as well
as the induction of analgesia by well-known analgesic
drugs such as opioids, tricyclic antidepressants, K2-adre-
noceptor agonists (Parenti et al., 1986; Sanchez-Blazquez
and Garzon, 1991; Galeotti et al., 1996).
As the Gi-proteins are widely distributed in the neural
areas, the function of a variety of cellular receptors is
expected to be altered by the impairing e¡ect of the
antisense treatment. It has been, therefore, necessary to
evaluate the possible induction of side e¡ects by the anti-
GiK treatment. The aODNs, at the highest doses used,
did not modify animals’ gross behaviour. Moreover,
additional behavioural tests were performed to illustrate
any side e¡ects produced by the treatments that cannot
be revealed by the researcher through the observation of
Fig. 6. Lack of e¡ect of pretreatment with an aODN to the K subunit of Gi1- (12.5 Wg per mouse i.c.v.), Gi2- (25 Wg per
mouse i.c.v.) and Gi3- (25 Wg per mouse i.c.v.) protein gene on spontaneous motility and inspection activity in the mouse
hole board test. The test was performed 18 h after the last i.c.v. injection of dODN (25 Wg per mouse) or aODN. Vertical
lines represent S.E.M. Twelve mice per group were tested. Amphet: D-amphetamine 1 mg kg31 i.p. *P6 0.05 in comparison
with saline group.
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the animal’s spontaneous behaviour. The aODN treat-
ment did not impair motor coordination, as revealed by
the progressive reduction of the number of falls in the
rota rod test. Repetition of the test session every 15 min
progressively decreases the number of falls since animals
learn how to balance on the rotating rod. The lack of
variation, or an increase in the number of falls after
treatment indicates an impairment of mice motor coor-
dination that could lead to a misinterpretation of the
results obtained in the analgesic test. Mice, even if still
sensitive to the thermal stimulus used in the hot-plate
test, may have no reaction to pain (licking of paws)
because of their impaired motility. Moreover, aODNs
did not modify spontaneous motility and exploratory
activity as indicated by the hole board test. We can,
thus, suppose that the e¡ects observed in the hot-plate
test were not imputable to compromised behavioural
paradigms.
Similarly, the administration of histamine H1 receptor
antagonists produces various inhibitory e¡ects including
sedation (Simons and Simons, 1994) whose appearance
could lead to a modi¢cation of the licking latency values
observed in the hot-plate test. At the doses employed,
diphenhydramine, pyrilamine and promethazine exerted
their antinociceptive activity without showing any alter-
ation of the mice motor coordination as revealed by the
rota rod test. Furthermore, the antihistamines did not
modify the spontaneous motility and the exploratory
activity as revealed by the hole board test (data not
shown).
In conclusion, present results evidence the important
role of Gi1, Gi2 and Gi3 protein subtypes in the mecha-
nism of analgesic action of diphenhydramine, pyrilamine
and promethazine.
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